Track Absci Corporation Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Absci Corporation Common Stock ABSI · Stock Open Absci Corporation Common Stock in new tab

8.45 USD
EPS
-0.79
P/B
6.66
ROE
-58.59
Beta
2.19
Target Price
14.82 USD
Absci Corporation Common Stock logo

Absci Corporation Common Stock

🧾 Earnings Recap – Q2 2026

Absci’s shares rose 5.4% following interim Phase I data that demonstrated favorable safety and pharmacokinetics for ABS-201, underpinning optimism around its potential dosing schedule and the strategic partnership with Eli Lilly.

  • Interim Phase I data show ABS-201 was well tolerated with a favorable safety and immunogenicity profile.
  • Pharmacokinetic results estimate a half-life of at least 65 days, supporting a dosing regimen of 2 to 3 injections over six months.
  • Strategic $40 million investment from Eli Lilly strengthens collaboration and includes Lilly participation on Absci’s endometriosis advisory board.
  • Absci completed a $100 million financing round, enabling ongoing development and pipeline expansion.
  • The Atlas platform is actively generating novel target hypotheses, including new indications for the prolactin receptor franchise, reflecting progress in leveraging AI-driven discovery.
📅
Loading chart...
Key Metrics
Earnings dateMarch 23, 2027
EPS-0.79
Book Value1.27
Price to Book6.66
Debt/Equity1.50
% Insiders11.782%
Growth
Revenue Growth-0.20%
Estimates
Forward P/E-12.28
Forward EPS-0.69
Target Mean Price14.82

DCF valuation

Model fair value for Absci Corporation Common Stock (ABSI)
Result
Sign in to run the valuation for ABSI.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
11 analysts · consensus Strong buy · mean target 14.82 USD (low 10.00, high 20.00) · as of 14 Nov 2026
Low 10.00
Mean 14.82
High 20.00
Price 8.45
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Absci Corporation Common Stock Logo Absci Corporation Common Stock Analysis (ABSI)

United States Health Care Official Website Stock

Is Absci Corporation Common Stock a good investment? Absci Corporation Common Stock (ABSI) is currently trading at 8.45 USD. Market analysts have a consensus price target of 14.82 USD. This suggests a potential upside from current levels.

Earnings Schedule: Absci Corporation Common Stock is expected to release its next earnings report on March 23, 2027. The market consensus estimate for Forward EPS is -0.69.

Investor FAQ

Does Absci Corporation Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Absci Corporation Common Stock?

Absci Corporation Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 23, 2027. The company currently has a trailing EPS of -0.79.

Company Profile

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Exchange Ticker
NMS (United States) ABSI
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion